Parente, Erika B.
Harjutsalo, Valma
Forsblom, Carol
Groop, Per-Henrik
,
Funding for this research was provided by:
Samfundet Folkhälsan
Academy of Finland (299200, 316664)
Wilhelm and Else Stockmann Foundation
Liv och Hälsa Society
Helsinki University Hospital Research Funds
Novo Nordisk Foundation (NNF OC0013659)
Finnish Diabetes Research Foundation
Article History
Received: 16 March 2021
Accepted: 9 July 2021
First Online: 27 July 2021
Declarations
:
: The study protocol was following the principles of the Declaration of Helsinki as revised in 2000 and was approved by the Ethical Committee of Helsinki and Uusimaa Hospital District. Written informed consents were obtained from each FinnDiane patient.
: Not applicable.
: EBP reports receiving lecture honorariums from Eli Lilly, Abbott, Astra Zeneca, Sanofi, Boehringer Ingelheim and is an advisory board member of Sanofi. P-H.G. reports receiving lecture honorariums from Astellas, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Medscape, MSD, Mundipharma, Novo Nordisk, PeerVoice, Sanofi, Sciarc and being an advisory board member of Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Novo Nordisk, and Sanofi. No other potential competing interests relevant to this article were reported. VH and CF report no competing interests.